Palo Alto, California-based drug delivery systems company increases size of planned offering of "liquid yield option" notes, or LYONs, due Dec. 21, 2010 from $600 mil. to $750 mil. Each LYON is being offered at a price of $229.34 per $1,000 principal amount at maturity. Merrill Lynch is underwriting the offering. Alza will net approximately $166.4 mil., which will be used for general corporate purposes.
You may also be interested in...
The SEEK spin-out ConserV Bioscience is developing a broad-spectrum coronavirus vaccine, aiming to get ahead of the arrival of new strains of the virus.
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.
CHF Solutions adds “CEO” to its president’s job title; Agilent VP of business development promoted to senior VP; Zimmer hires chief transformation officer; and more.